S-8

As filed with the Securities and Exchange Commission on March 7, 2018

Registration No. 333-            

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 

CytomX Therapeutics, Inc.

(Exact name of Registrant as specified in its charter)

 

 

 

Delaware   2834   27-3521219

(State or other jurisdiction of

incorporation or organization)

 

Primary Standard Industrial

Classification Code Number)

 

(I.R.S. Employer

Identification Number)

151 Oyster Point Blvd.

Suite 400

South San Francisco, CA 94080

(650) 515-3185

(Address, including zip code, and telephone number, including area code, of Registrant’s principal executive offices)

 

 

CytomX Therapeutics, Inc. 2015 Equity Incentive Plan

CytomX Therapeutics, Inc. Employee Stock Purchase Plan

(Full Title of the Plan)

 

 

Sean A. McCarthy, D.Phil.

President and Chief Executive Officer

CytomX Therapeutics, Inc.

151 Oyster Point Blvd., Suite 400

South San Francisco, CA 94080

(650) 515-3185

(Name, address, including zip code, and telephone number, including area code, of agent for service)

 

 

Copies to:

Mark V. Roeder, Esq.

Latham & Watkins LLP

140 Scott Drive

Menlo Park, California 94025

(650) 328-4600

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer      Accelerated filer  
Non-accelerated filer   ☐  (Do not check if a smaller reporting company)    Smaller reporting company  
     Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for comply with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act.  ☒

 

 

CALCULATION OF REGISTRATION FEE

 

 

Title of Each Class of

Securities to be Registered

 

Amount

to be

Registered(1)

 

Proposed

Maximum
Offering Price

Per Share(2)

 

Proposed

Maximum
Aggregate

Offering Price

Per Share

  Amount of
Registration Fee

Common Stock, par value $0.00001 per share

  1,539,142 shares(3)    $32.33   $49,760,460.86   $6,195.18

Common Stock, par value $0.00001 per share

  384,785 shares (4)   $32.33   $12,440,099.05   $1,548.79

Total:

  1,923,927 shares   $32.33   $62,200,559.91   $7,743.97

 

 

(1) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement shall also cover any additional shares of the Registrant’s common stock that become issuable under the CytomX Therapeutics, Inc. 2015 Equity Incentive Plan (the “2015 Plan”) and the CytomX Therapeutics, Inc. Employee Stock Purchase Plan (the “ESPP”) by reason of any stock dividend, stock split, recapitalization or similar transaction effected without the Registrant’s receipt of consideration which would increase the number of outstanding shares of common stock.
(2) This estimate is made pursuant to Rule 457(c) and Rule 457(h) of the Securities Act solely for purposes of calculating the registration fee. The Proposed Maximum Offering Price Per Share for shares available for future grant is the average of the high and low prices for the registrant’s common stock as reported on The NASDAQ Global Select Market on March 6, 2018, which is $32.33.
(3) Represents the additional shares of common stock available for future issuance under the 2015 Plan resulting from an annual increase as of January 1, 2018.
(4) Represents the additional shares of common stock available for future issuance under the ESPP resulting from an annual increase as of January 1, 2018.

Proposed sale to take place as soon after the effective date of the

registration statement as awards under the plans are exercised and/or vest.

 

 

 


EXPLANATORY NOTE

This Registration Statement on Form S-8 is being filed for the purpose of registering an additional 1,923,927 shares of the Registrant’s common stock issuable under the following employee benefit plans for which Registration Statements of the Registrant on Form S-8 (File Nos. 333-207694, 333-209992 and 333-215795) are effective: (i) the CytomX Therapeutics, Inc. 2015 Equity Incentive Plan, as a result of the operation of an automatic annual increase provision therein, which added 1,539,142 shares of common stock, and (ii) the CytomX Therapeutics, Inc. Employee Stock Purchase Plan, as a result of the operation of an automatic annual increase provision therein, which added 384,785 shares of common stock.

INCORPORATION BY REFERENCE OF CONTENTS OF REGISTRATION STATEMENT ON FORM S-8

Pursuant to Instruction E of Form S-8, the contents of the Registration Statements on Form S-8 filed with the Securities and Exchange Commission on October 30, 2015 (File No. 333-207694), March 7, 2016 (File No. 333-209992) and January 27, 2017 (File No. 333-215795) are incorporated by reference herein; except for Item 8 which is being updated by this Registration Statement.

 

Item 8. Exhibits

 

        

Incorporated by Reference

  

Filed

Herewith

Exhibit

Number

  Exhibit Description    Form    Date    Number     
  4.1   Amended and Restated Certificate of Incorporation.    8-K    10/19/2015    3.1   
  4.2   Amended and Restated Bylaws.    8-K    10/19/2015    3.2   
  4.3   Form of Common Stock Certificate.    S-1/A    9/28/2015    4.1   
  4.4   Amended and Restated Investors’ Rights Agreement dated as of June  12, 2015, by and among CytomX Therapeutics, Inc. and the investors named therein.    S-1/A    8/28/2015    4.2   
  4.5   Registration Rights Agreement dated as of September 29, 2017 by and between CytomX Therapeutics, Inc. and Amgen, Inc.    10-Q    11/7/207    4.4   
  5.1   Opinion of Latham & Watkins LLP.             X
23.1   Consent of Ernst & Young LLP, Independent Registered Accounting Firm.             X
23.2   Consent of PricewaterhouseCoopers LLP, Independent Registered Accounting Firm             X
23.3   Consent of Latham & Watkins LLP (included in Exhibit 5.1).             X
24.1   Power of Attorney. Reference is made to the signature page to the Registration Statement.             X
99.1(a)#   CytomX Therapeutics, Inc. 2015 Equity Incentive Plan.    S-1/A    10/6/2015    10.5   
99.1(b)#   Form of Option Award Notice under the CytomX Therapeutics, Inc. 2015 Equity Incentive Plan.    10-Q    11/23/2015    10.4   
99.1(c)#   Form of Early Exercise Option Award Notice under the CytomX Therapeutics, Inc. 2015 Equity Incentive Plan.    10-Q    11/23/2015    10.5   

 

# Indicates management contract or compensatory plan.


SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in South San Francisco, California, on this 7th day of March, 2018.

 

CytomX Therapeutics, Inc.
By:  

/s/ Sean A. McCarthy

  Sean A. McCarthy, D.Phil.
  President and Chief Executive Officer

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below does hereby constitute and appoint Sean A. McCarthy and Debanjan Ray, and each of them, with full power of substitution and full power to act without the other, his or her true and lawful attorney-in-fact and agent to act for him or her in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file this registration statement, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in order to effectuate the same as fully, to all intents and purposes, as they or he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the date indicated.

 

Signature

  

Title

 

Date

/s/ Sean A. McCarthy

Sean A. McCarthy, D.Phil

  

President, Chief Executive Officer and Director

(Principal Executive Officer)

  March 7, 2018

/s/ Debanjan Ray

Debanjan Ray

  

Chief Financial Officer

(Principal Financial and Accounting Officer)

  March 7, 2018

/s/ Hoyoung Huh

Hoyoung Huh, M.D. Ph.D.

   Director   March 7, 2018

/s/ Charles S. Fuchs

Charles S. Fuchs, M.D., M.P.H.

   Director   March 7, 2018

/s/ Frederick W. Gluck

Frederick W. Gluck

   Director   March 7, 2018

/s/ Marion McCourt

Marion McCourt

   Director   March 7, 2018

/s/ John A. Scarlett

John A. Scarlett, M.D.

   Director   March 7, 2018

/s/ Matthew P. Young

Matthew P. Young

   Director   March 7, 2018
EX-5.1

Exhibit 5.1

 

 

140 Scott Drive

 

Menlo Park, California 94025

 

Tel: +1.650.328.4600 Fax: +1.650.463.2600

 

www.lw.com

LOGO  

FIRM / AFFILIATE OFFICES

 

Beijing

  

Moscow

 

Boston

  

Munich

 

Brussels

  

New York

 

Century City

  

Orange County

 

Chicago

  

Paris

 

Dubai

  

Riyadh

March 7, 2018  

Düsseldorf

  

Rome

 

Frankfurt

  

San Diego

 

Hamburg

  

San Francisco

 

Hong Kong

  

Seoul

 

Houston

  

Shanghai

 

London

  

Silicon Valley

 

Los Angeles

  

Singapore

 

Madrid

  

Tokyo

 

Milan

  

Washington, D.C.

CytomX Therapeutics, Inc.

151 Oyster Point Blvd., Suite 400

South San Francisco, CA 94080

 

  Re: Registration Statement on Form S-8; 1,923,927 shares of Common Stock of CytomX Therapeutics, Inc., par value $0.00001 per share

Ladies and Gentlemen:

We have acted as special counsel to CytomX Therapeutics, Inc., a Delaware corporation (the “Company”), in connection with the registration by the Company of an aggregate of 1,923,927 shares of common stock of the Company, par value $0.00001 per share (the “Common Stock”), consisting of 1,539,142 shares of Common Stock (the “2015 Plan Shares”) issuable under the CytomX Therapeutics, Inc. 2015 Equity Incentive Plan (the “2015 Plan”) and 384,785 shares of Common Stock (the “ESPP Shares” and, together with the 2015 Plan Shares, the “Shares”) issuable under the CytomX Therapeutics, Inc. Employee Stock Purchase Plan (the “ESPP” and together with the 2015 Plan, the “Plans”).

The Shares are included in a registration statement on Form S–8 under the Securities Act of 1933, as amended (the “Act”), filed with the Securities and Exchange Commission (the “Commission”) on March 7, 2018 (the “Registration Statement”). This opinion is being furnished in connection with the requirements of Item 601(b)(5) of Regulation S-K under the Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement or the related prospectuses, other than as expressly stated herein with respect to the issue of the Shares.

As such counsel, we have examined such matters of fact and questions of law as we have considered appropriate for purposes of this letter. With your consent, we have relied upon certificates and other assurances of officers of the Company and others as to factual matters


March 7, 2018

Page 2

 

LOGO

 

without having independently verified such factual matters. We are opining herein as to the General Corporation Law of the State of Delaware (the “DGCL”), and we express no opinion with respect to any other laws.

Subject to the foregoing and the other matters set forth herein, it is our opinion that, as of the date hereof, when the Shares shall have been duly registered on the books of the transfer agent and registrar therefor in the name or on behalf of the purchasers and have been issued by the Company against payment therefor in the circumstances contemplated by the Plans, assuming in each case that the individual issuances, grants or awards under the Plans are duly authorized by all necessary corporate action and duly issued, granted or awarded and exercised in accordance with the requirements of law and the Plans (and the agreements and awards duly adopted thereunder and in accordance therewith), the issuance and sale of the Shares will have been duly authorized by all necessary corporate action of the Company, and the Shares will be validly issued, fully paid and nonassessable. In rendering the foregoing opinion, we have assumed that the Company will comply with all applicable notice requirements regarding uncertificated shares provided in the DGCL.

This opinion is for your benefit in connection with the Registration Statement and may be relied upon by you and by persons entitled to rely upon it pursuant to the applicable provisions of the Act. We consent to your filing this opinion as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Act or the rules and regulations of the Commission thereunder.

 

Very truly yours,
/s/ Latham & Watkins LLP
EX-23.1

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the CytomX Therapeutics, Inc. 2015 Equity Incentive Plan and the CytomX Therapeutics, Inc. Employee Stock Purchase Plan of our report dated March 7, 2018, with respect to the consolidated financial statements of CytomX Therapeutics, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2017, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

Redwood City, California

March 7, 2018

EX-23.2

Exhibit 23.2

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of CytomX Therapeutics, Inc. of our report dated March 2, 2017 relating to the financial statements, which appears in CytomX Therapeutics, Inc.’s Annual Report on Form 10-K for the year ended December 31, 2017.

/s/ PricewaterhouseCoopers

San Jose, CA

March 7, 2018